BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ovarian Cancer readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Ovarian Cancer\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05456685-11140@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT05456
 685)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2\, Ovarian Cancer.
 \nStudy: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line 
 Treatment of Folate Receptor Alpha (FRα) Expressing\, Platinum-sensitive 
 Epithelial Ovarian Cancer\nEstimated primary completion: November 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/mirvetuximab-soravtansi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5456685
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06840002-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06840002)
DESCRIPTION:Bevacizumab\, phase 1/2\, Ovarian Cancer.\nStudy: A Clinical St
 udy of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurre
 nt Ovarian Cancer\nEstimated primary completion: December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06840002
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06840002-9096@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab rezetecan: Phase 1/2 readout est. (NCT06840002)
DESCRIPTION:Trastuzumab rezetecan\, phase 1/2\, Ovarian Cancer.\nStudy: A C
 linical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensiti
 ve Recurrent Ovarian Cancer\nEstimated primary completion: December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT068
 40002
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02644369-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT02644369)
DESCRIPTION:Pembrolizumab\, phase 2\, Ovarian Cancer.\nStudy: Study of the 
 Effects of Pembrolizumab in Patients With Advanced Solid Tumors\nEstimated
  primary completion: December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT02644369
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05281471-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05281471)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: Efficacy & Safe
 ty of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's 
 Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ov
 arian Cancer (PRROC) (OnPrime\, GOG-3076)\nEstimated primary completion: D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevaciz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05281471
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05281471-2654@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Olvimulogene nanivacirepvec: Phase 3 readout est. (NCT05281471)
DESCRIPTION:Olvimulogene nanivacirepvec\, phase 3\, Ovarian Cancer.\nStudy:
  Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared
  to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resista
 nt/Refractory Ovarian Cancer (PRROC) (OnPrime\, GOG-3076)\nEstimated prima
 ry completion: December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/olvimulogene-nanivacirepvec#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05281471
URL:https://assetmemo.bio/drug/olvimulogene-nanivacirepvec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585750-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04585750)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harborin
 g a TP53 Y220C Mutation (PYNNACLE)\nEstimated primary completion: 15 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4585750
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585750-2704@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:rezatapopt: Phase 1/2 readout est. (NCT04585750)
DESCRIPTION:rezatapopt\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Th
 e Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a
  TP53 Y220C Mutation (PYNNACLE)\nEstimated primary completion: 15 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/rezatapopt#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0458575
 0
URL:https://assetmemo.bio/drug/rezatapopt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05335993-2052@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Niraparib: Phase 2 readout est. (NCT05335993)
DESCRIPTION:Niraparib\, phase 2\, Ovarian Cancer.\nStudy: A Clinical Study 
 Evaluating a Combination of Oregovomab and Niraparib in Adult Women With P
 latinum Sensitive Recurrent Ovarian Cancer.\nEstimated primary completion:
  30 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ni
 raparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05335993
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340164-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07340164)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Trastzumab Deru
 xtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhib
 itor Therapy\nEstimated primary completion: 30 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07340164
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140526-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04140526)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Safety\, PK and Efficacy of ONC-392 in Monotherapy and in Combination of 
 Anti-PD-1 in Advanced Solid Tumors and NSCLC\nEstimated primary completion
 : 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04140526
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04918186-1959@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04918186)
DESCRIPTION:Durvalumab\, phase 2\, Ovarian Cancer.\nStudy: Immunotherapy Pl
 atform Study in Platinum Resistant High Grade Serous Ovarian Cancer\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04918186
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05114421-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05114421)
DESCRIPTION:Pembrolizumab\, phase 2\, Ovarian Cancer.\nStudy: Pembrolizumab
  and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients\nEstim
 ated primary completion: 31 January 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05114421
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06365853-11140@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT06365
 853)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2\, Ovarian Cancer.
 \nStudy: A Study of Ocular Toxicity Evaluation and Mitigation During Treat
 ment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian
  Cancer With High Folate Receptor-Alpha Expression\nEstimated primary comp
 letion: February 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/mirvetuximab-soravtansine#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06365853
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05183984-2052@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Niraparib: Phase 2 readout est. (NCT05183984)
DESCRIPTION:Niraparib\, phase 2\, Ovarian Cancer.\nStudy: Niraparib With be
 VAcizumab After Complete cytoreductioN in Patients With ovArian Cancer\nEs
 timated primary completion: February 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/niraparib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05183984
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02884648-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT02884648)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Bevacizumab in 
 Ovarian Cancer Patients With Disease at Second-Look Surgery\nEstimated pri
 mary completion: 2 February 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT02884648
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05271318-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05271318)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Ovarian Cancer.\nStudy: Oncolytic A
 denovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrol
 izumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatm
 ent for Ovarian Cancer.\nEstimated primary completion: March 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05271318
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06888921-10869@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:COM701: Phase 1/2 readout est. (NCT06888921)
DESCRIPTION:COM701\, phase 1/2\, Ovarian Cancer.\nStudy: A Clinical Trial t
 o Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitiv
 e Ovarian Cancer\nEstimated primary completion: March 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/com701#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06888921
URL:https://assetmemo.bio/drug/com701#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06141265-2052@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Niraparib: Phase 2 readout est. (NCT06141265)
DESCRIPTION:Niraparib\, phase 2\, Ovarian Cancer.\nStudy: Niraparib Mainten
 ance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemothe
 rapy + Bevacizumab\nEstimated primary completion: March 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/niraparib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06141265
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03878849-10856@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:stenoparib: Phase 2 readout est. (NCT03878849)
DESCRIPTION:stenoparib\, phase 2\, Ovarian Cancer.\nStudy: Investigation of
  the Anti-tumor Effect of 2X-121 in Patients With Recurrent\, Advanced Ova
 rian Cancer\nEstimated primary completion: March 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/stenoparib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03878849
URL:https://assetmemo.bio/drug/stenoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05231122-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270315
DTEND;VALUE=DATE:20270316
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05231122)
DESCRIPTION:Pembrolizumab\, phase 2\, Ovarian Cancer.\nStudy: Pembrolizumab
  Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for 
 the Treatment of Patients With Recurrent Ovarian Cancer\nEstimated primary
  completion: 15 March 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05231122
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05231122-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270315
DTEND;VALUE=DATE:20270316
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05231122)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Pembrolizumab C
 ombined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for th
 e Treatment of Patients With Recurrent Ovarian Cancer\nEstimated primary c
 ompletion: 15 March 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05231122
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06594679-2052@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270320
DTEND;VALUE=DATE:20270321
SUMMARY:Niraparib: Phase 1/2 readout est. (NCT06594679)
DESCRIPTION:Niraparib\, phase 1/2\, Ovarian Cancer.\nStudy: A Study of Nira
 parib in Combination With Abemaciclib for Late Line Treatment of Ovarian C
 ancer (NICHOL TRIAL)\nEstimated primary completion: 20 March 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/niraparib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06594679
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07453394-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07453394)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Q
 LS5132 Combination Therapy in Advanced Solid Tumors\nEstimated primary com
 pletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07453394
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07453394-2028@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT07453394)
DESCRIPTION:Olaparib\, phase 1/2\, Ovarian Cancer.\nStudy: QLS5132 Combinat
 ion Therapy in Advanced Solid Tumors\nEstimated primary completion: April 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07453394
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06394804-11026@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 2 readout
  est. (NCT06394804)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 2\, 
 Ovarian Cancer.\nStudy: A Study of Avutometinib\, Defactinib\, and Letrozo
 le in People With Low-Grade Serous Ovarian Cancer\nEstimated primary compl
 etion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/av
 utometinib-defactinib-avmapki-fakzynja-co-pack#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06394804
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05445778-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05445778)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: Mirvetuximab So
 ravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-
 sensitive Epithelial Ovarian\, Fallopian Tube\, or Peritoneal Cancer\nEsti
 mated primary completion: April 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05445778
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05445778-11140@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 3 readout est. (NCT05445
 778)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 3\, Ovarian Cancer.
 \nStudy: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as 
 Maintenance in Platinum-sensitive Epithelial Ovarian\, Fallopian Tube\, or
  Peritoneal Cancer\nEstimated primary completion: April 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05445778
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04421963-2028@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Olaparib: Phase 3 readout est. (NCT04421963)
DESCRIPTION:Olaparib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Roll Over StudY for Patients Who Have Completed a Previous Oncology Stud
 y With Olaparib\nEstimated primary completion: 6 April 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04421963
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07023627-10796@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:INCB123667: Phase 2 readout est. (NCT07023627)
DESCRIPTION:INCB123667\, phase 2\, Ovarian Cancer.\nStudy: A Study of INCB1
 23667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E
 1 Overexpression\nEstimated primary completion: 27 April 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/incb123667#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07023627
URL:https://assetmemo.bio/drug/incb123667#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06799065-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06799065)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: F
 irst-in-Human Study of ATX-295\, an Oral Inhibitor of KIF18A\, as Monother
 apy and in Combination With Anticancer Therapy in Patients With Advanced o
 r Metastatic Solid Tumors\, Including Ovarian Cancer\nEstimated primary co
 mpletion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06799065
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06828354-9096@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT06828354)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Ovarian Cancer.\nStudy: A Stu
 dy of SHR-A1811 in Subjects With Ovarian Cancer\nEstimated primary complet
 ion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastu
 zumab-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06828354
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07460180-2028@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT07460180)
DESCRIPTION:Olaparib\, phase 1/2\, Ovarian Cancer.\nStudy: The PROOV Study:
  Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and H
 yperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Can
 cer\nEstimated primary completion: 1 May 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07460180
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03564340-2789@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:Ubamatamab: Phase 1/2 readout est. (NCT03564340)
DESCRIPTION:Ubamatamab\, phase 1/2\, Ovarian Cancer.\nStudy: Study of REGN4
 018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in A
 dult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Ex
 pressing (MUC16+) Cancers\nEstimated primary completion: 10 May 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/ubamatamab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT03564340
URL:https://assetmemo.bio/drug/ubamatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06420973-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06420973)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: RC48 Treatment 
 for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression\nEsti
 mated primary completion: 17 May 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06420973
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06994195-2044@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT06994195)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Ovarian Cancer.\nStudy: A S
 tudy Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in 
 Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU
 -GYN01)\nEstimated primary completion: June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06994195
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05739981-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05739981)
DESCRIPTION:Bevacizumab\, phase 1/2\, Ovarian Cancer.\nStudy: Phase II IMNN
 -001 (Also Known as GEN-1) on SLL With BEV and NACT\, Newly Diagnosed Adva
 nced Ovarian\, Fallopian Tube or Primary Peritoneal Cancer\nEstimated prim
 ary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05739981
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07741630-11140@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT07741
 630)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2\, Ovarian Cancer.
 \nStudy: Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Re
 sistant Recurrent Ovarian Cancer\nEstimated primary completion: 30 June 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/mirvetuximab-sora
 vtansine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07741630
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04606914-11140@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT04606
 914)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2\, Ovarian Cancer.
 \nStudy: Study of Carboplatin and Mirvetuximab Soravtansine in First-Line 
 Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Sta
 ge Ovarian\, Fallopian Tube or Primary Peritoneal Cancer\nEstimated primar
 y completion: July 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/mirvetuximab-soravtansine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04606914
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05081609-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05081609)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alo
 ne or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or 
 Other Anticancer Therapies in Adult Participants With Locally Advanced or 
 Metastatic Solid Tumor Malignancies\nEstimated primary completion: August 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05081
 609
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07747506-11026@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 2 readout
  est. (NCT07747506)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 2\, 
 Ovarian Cancer.\nStudy: Continued Access to Avutometinib in Combination Wi
 th Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (
 LGSOC)\nEstimated primary completion: 1 August 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-c
 o-pack#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07747506
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604766-2708@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 3 readout est. (NCT07604766)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 3\, Ovarian Cancer.\nStud
 y: An Extension Study to Assess the Efficacy of Rina-S Compared to Treatme
 nt of Investigator's Choice in Participants With Platinum Resistant Ovaria
 n Cancer in China\nEstimated primary completion: September 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076047
 66
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06083844-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06083844)
DESCRIPTION:Pembrolizumab\, phase 2\, Ovarian Cancer.\nStudy: Phase II Inve
 stigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclop
 hosphamide in Patients With High Grade Ovarian Cancer and Surgically Docum
 ented Minimal Residual Disease After Frontline Therapy\nEstimated primary 
 completion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06083844
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06083844-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06083844)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Phase II Invest
 igation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclopho
 sphamide in Patients With High Grade Ovarian Cancer and Surgically Documen
 ted Minimal Residual Disease After Frontline Therapy\nEstimated primary co
 mpletion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06083844
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06690775-2773@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Ixotatug vedotin: Phase 2 readout est. (NCT06690775)
DESCRIPTION:Ixotatug vedotin\, phase 2\, Ovarian Cancer.\nStudy: CATALINA-2
 : A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.\nEst
 imated primary completion: October 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ixotatug-vedotin#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06690775
URL:https://assetmemo.bio/drug/ixotatug-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06686030-2028@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Olaparib: Phase 2 readout est. (NCT06686030)
DESCRIPTION:Olaparib\, phase 2\, Ovarian Cancer.\nStudy: Combination Therap
 y of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian
  Cancer\nEstimated primary completion: October 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06686030
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05489211-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05489211)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Study of Dato-D
 Xd as Monotherapy and in Combination With Anti-cancer Agents in Patients W
 ith Advanced Solid Tumours (TROPION-PanTumor03)\nEstimated primary complet
 ion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05489211
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07214779-10796@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:INCB123667: Phase 3 readout est. (NCT07214779)
DESCRIPTION:INCB123667\, phase 3\, Ovarian Cancer.\nStudy: Study to Evaluat
 e INCB123667 Versus Investigator's Choice of Chemotherapy in Participants 
 With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression\nEsti
 mated primary completion: 12 October 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/incb123667#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07214779
URL:https://assetmemo.bio/drug/incb123667#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933419-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271115
DTEND;VALUE=DATE:20271116
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07933419)
DESCRIPTION:Bevacizumab\, phase 1/2\, Ovarian Cancer.\nStudy: Phase Ib/II C
 linical Study of QLS5133 Combination Therapy in Advanced Solid Tumors\nEst
 imated primary completion: 15 November 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07933419
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933419-2028@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271115
DTEND;VALUE=DATE:20271116
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT07933419)
DESCRIPTION:Olaparib\, phase 1/2\, Ovarian Cancer.\nStudy: Phase Ib/II Clin
 ical Study of QLS5133 Combination Therapy in Advanced Solid Tumors\nEstima
 ted primary completion: 15 November 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07933419
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07261683-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07261683)
DESCRIPTION:Pembrolizumab\, phase 2\, Ovarian Cancer.\nStudy: Phase II Stud
 y of Weekly Paclitaxel/Nab-Paclitaxel\, Pembrolizumab\, and Mirabegron for
  Recurrent Ovarian Cancer\nEstimated primary completion: 30 November 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07261683
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06303505-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06303505)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: F
 iH Study to Investigate Safety\, PK and Efficacy of the NaPi2b ADC TUB-040
  in Patients With PROC or r/r Adenocarcinoma NSCLC\nEstimated primary comp
 letion: December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06303505
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07322094-2773@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ixotatug vedotin: Phase 1/2 readout est. (NCT07322094)
DESCRIPTION:Ixotatug vedotin\, phase 1/2\, Ovarian Cancer.\nStudy: CATALINA
 -4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemo
 therapy Given Before Initial Surgery in Women With Advanced Stage Ovarian 
 Cancer\nEstimated primary completion: December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ixotatug-vedotin#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07322094
URL:https://assetmemo.bio/drug/ixotatug-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06303505-2785@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:TUB-040: Phase 1/2 readout est. (NCT06303505)
DESCRIPTION:TUB-040\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: FiH S
 tudy to Investigate Safety\, PK and Efficacy of the NaPi2b ADC TUB-040 in 
 Patients With PROC or r/r Adenocarcinoma NSCLC\nEstimated primary completi
 on: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tu
 b-040#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06303505
URL:https://assetmemo.bio/drug/tub-040#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06906341-399@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Relacorilant (Lifyorli): Phase 2 readout est. (NCT06906341)
DESCRIPTION:Relacorilant (Lifyorli)\, phase 2\, Ovarian Cancer.\nStudy: Rel
 acorilant in Combination With Different Treatment Regimens in Patients Wit
 h Gynecological Cancers\nEstimated primary completion: December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/relacorilant-lifyorli#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0690634
 1
URL:https://assetmemo.bio/drug/relacorilant-lifyorli#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06906341-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06906341)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Relacorilant in
  Combination With Different Treatment Regimens in Patients With Gynecologi
 cal Cancers\nEstimated primary completion: December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06906341
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05512208-11026@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 2 readout
  est. (NCT05512208)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 2\, 
 Ovarian Cancer.\nStudy: A Phase 2 Study of Avutometinib (VS-6766) Plus Def
 actinib\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-
 co-pack#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05512208
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07042802-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271225
DTEND;VALUE=DATE:20271226
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07042802)
DESCRIPTION:Bevacizumab\, phase 1/2\, Ovarian Cancer.\nStudy: A Study of LB
 L-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of P
 latinum-resistant Ovarian Cancer\nEstimated primary completion: 25 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07042
 802
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07314619-1991@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07314619)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Ovarian Cancer.\nStudy: Pro
 spective\, Multicenter\, Single-Arm\, Phase Ⅱ Clinical Study on the Effi
 cacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Pl
 atinum-Resistant Recurrent Ovarian Cancer\nEstimated primary completion: 3
 0 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/saci
 tuzumab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07314619
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07314619-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07314619)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Prospective\, M
 ulticenter\, Single-Arm\, Phase Ⅱ Clinical Study on the Efficacy and Saf
 ety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resis
 tant Recurrent Ovarian Cancer\nEstimated primary completion: 30 December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07314619
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07311577-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07311577)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Disitamab Vedot
 in Combined With Platinum and Bevacizumab as First-Line and Maintenance Th
 erapy for HER2-Expressing\, HRD-Negative High-Risk Ovarian Cancer: A Multi
 center\, Non-Randomized\, Single-Arm Phase II Clinical Study\nEstimated pr
 imary completion: 30 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07311577
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02726997-1959@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT02726997)
DESCRIPTION:Durvalumab\, phase 1/2\, Ovarian Cancer.\nStudy: Matched Paired
  Pharmacodynamics and Feasibility Study of Durvalumab in Combination With 
 Chemotherapy in Frontline Ovarian Cancer (N-Dur)\nEstimated primary comple
 tion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT02726997
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02489006-2028@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Olaparib: Phase 2 readout est. (NCT02489006)
DESCRIPTION:Olaparib\, phase 2\, Ovarian Cancer.\nStudy: A Study of Olapari
 b Prior to Surgery and Chemotherapy in Ovarian\, Primary Peritoneal\, and 
 Fallopian Tube Cancer\nEstimated primary completion: 31 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT02489006
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407452-2028@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Olaparib: Phase 2 readout est. (NCT07407452)
DESCRIPTION:Olaparib\, phase 2\, Ovarian Cancer.\nStudy: Iparomlimab and Tu
 vonralimab (QL1706) Combined With Standard Chemotherapy or Combined With I
 ntraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy 
 for Advanced Ovarian Cancer\nEstimated primary completion: 31 December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07407452
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07667751-2028@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Olaparib: Phase 2 readout est. (NCT07667751)
DESCRIPTION:Olaparib\, phase 2\, Ovarian Cancer.\nStudy: An Exploratory Stu
 dy on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Ola
 parib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer\nEst
 imated primary completion: 31 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07667751
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05990192-2052@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Niraparib: Phase 2 readout est. (NCT05990192)
DESCRIPTION:Niraparib\, phase 2\, Ovarian Cancer.\nStudy: SBRT Alone or Fol
 lowed by Niraparib for Oligometastases or Oligoprogression in Ovarian Canc
 er Following PARPi Therapy\nEstimated primary completion: 31 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/niraparib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05990192
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04644289-1959@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04644289)
DESCRIPTION:Durvalumab\, phase 2\, Ovarian Cancer.\nStudy: WoO: Window of O
 pportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC\n
 Estimated primary completion: January 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04644289
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07024784-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07024784)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: A Study to Asse
 ss Change in Disease Activity and Adverse Events in Adult Participants Wit
 h Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monothe
 rapy or in Combination With Other Therapies\nEstimated primary completion:
  January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevaci
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07024784
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04644289-2028@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Olaparib: Phase 2 readout est. (NCT04644289)
DESCRIPTION:Olaparib\, phase 2\, Ovarian Cancer.\nStudy: WoO: Window of Opp
 ortunity Trial of Olaparib and Durvalumab in Histologically Proven EOC\nEs
 timated primary completion: January 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04644289
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07024784-2028@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Olaparib: Phase 2 readout est. (NCT07024784)
DESCRIPTION:Olaparib\, phase 2\, Ovarian Cancer.\nStudy: A Study to Assess 
 Change in Disease Activity and Adverse Events in Adult Participants With G
 ynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherap
 y or in Combination With Other Therapies\nEstimated primary completion: Ja
 nuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olaparib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0702
 4784
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06180356-2052@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Niraparib: Phase 2 readout est. (NCT06180356)
DESCRIPTION:Niraparib\, phase 2\, Ovarian Cancer.\nStudy: Niraparib Rechall
 enge After Surgery in Ovarian Cancer Patients With Oligometastatic Progres
 sion\nEstimated primary completion: January 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/niraparib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06180356
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05255471-2028@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280121
DTEND;VALUE=DATE:20280122
SUMMARY:Olaparib: Phase 3 readout est. (NCT05255471)
DESCRIPTION:Olaparib\, phase 3\, Ovarian Cancer.\nStudy: MITO 35B: Olaparib
  Beyond Progression Compared to Platinum Chemotherapy After Secondary Cyto
 reductive Surgery in Recurrent Ovarian Cancer Patients.\nEstimated primary
  completion: 21 January 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/olaparib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05255471
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04752826-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04752826)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Ovarian Cancer.\nStudy: BI-1808 as 
 a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanc
 ed Malignancies(Keynote-D20)\nEstimated primary completion: 31 January 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04752826
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04931342-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT04931342)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: A Study Evaluat
 ing the Efficacy and Safety of Biomarker-Driven Therapies in Patients With
  Persistent or Recurrent Rare Epithelial Ovarian Tumors\nEstimated primary
  completion: 28 February 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT04931342
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04931342-2028@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Olaparib: Phase 2 readout est. (NCT04931342)
DESCRIPTION:Olaparib\, phase 2\, Ovarian Cancer.\nStudy: A Study Evaluating
  the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Pe
 rsistent or Recurrent Rare Epithelial Ovarian Tumors\nEstimated primary co
 mpletion: 28 February 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/olaparib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04931342
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07736937-2785@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:TUB-040: Phase 1/2 readout est. (NCT07736937)
DESCRIPTION:TUB-040\, phase 1/2\, Ovarian Cancer.\nStudy: Study of TUB-040 
 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ova
 rian Cancer\nEstimated primary completion: March 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tub-040#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07736937
URL:https://assetmemo.bio/drug/tub-040#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03412877-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280323
DTEND;VALUE=DATE:20280324
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03412877)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
 dministration of Autologous T-Cells Genetically Engineered to Express T-Ce
 ll Receptors Reactive Against Neoantigens in People With Metastatic Cancer
 \nEstimated primary completion: 23 March 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03412877
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07776171-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07776171)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Trastuzumab Rez
 etecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemoth
 erapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer\nEstima
 ted primary completion: 30 March 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07776171
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07776171-9096@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07776171)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Ovarian Cancer.\nStudy: Trast
 uzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choi
 ce Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Canc
 er\nEstimated primary completion: 30 March 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07776171
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07714668-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07714668)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: A Clinical Stud
 y of SYS6041 Combination Therapy for Recurrent Ovarian Cancer\nEstimated p
 rimary completion: 30 April 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07714668
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06971744-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280618
DTEND;VALUE=DATE:20280619
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06971744)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Autophagy Maint
 enance (AUTOMAIN)\nEstimated primary completion: 18 June 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06971744
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07934121-11140@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT07934
 121)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2\, Ovarian Cancer.
 \nStudy: MIRV in Combination With Suvemcitug for Partially Platinum-Sensit
 ive Ovarian Cancer\nEstimated primary completion: 30 June 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07934121
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06787612-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06787612)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Investigation o
 f Ubamatamab Combination Therapy in Adult Participants With Platinum-Resis
 tant Ovarian Cancer\nEstimated primary completion: 30 June 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06787612
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06787612-2789@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Ubamatamab: Phase 2 readout est. (NCT06787612)
DESCRIPTION:Ubamatamab\, phase 2\, Ovarian Cancer.\nStudy: Investigation of
  Ubamatamab Combination Therapy in Adult Participants With Platinum-Resist
 ant Ovarian Cancer\nEstimated primary completion: 30 June 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ubamatamab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06787612
URL:https://assetmemo.bio/drug/ubamatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07634094-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07634094)
DESCRIPTION:Pembrolizumab\, phase 2\, Ovarian Cancer.\nStudy: Intensive Loc
 oregional Chemoimmunotherapy\, Intradermal Autologous Alpha-DC1 Vaccines\,
  and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer\nEstimated p
 rimary completion: August 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07634094
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05797168-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280804
DTEND;VALUE=DATE:20280805
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05797168)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Pa
 rticipants With Solid Tumors\nEstimated primary completion: 4 August 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05797168
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05797168-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280804
DTEND;VALUE=DATE:20280805
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05797168)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: P
 hase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Part
 icipants With Solid Tumors\nEstimated primary completion: 4 August 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05797168
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05797168-11153@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280804
DTEND;VALUE=DATE:20280805
SUMMARY:Torvutatug samrotecan: Phase 1/2 readout est. (NCT05797168)
DESCRIPTION:Torvutatug samrotecan\, phase 1/2\, Ovarian Cancer.\nStudy: Pha
 se I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Partic
 ipants With Solid Tumors\nEstimated primary completion: 4 August 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/torvutatug-samrotecan#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT057971
 68
URL:https://assetmemo.bio/drug/torvutatug-samrotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07637851-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07637851)
DESCRIPTION:Bevacizumab\, phase 1/2\, Ovarian Cancer.\nStudy: Safety and Ef
 ficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer\nEstim
 ated primary completion: September 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07637851
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07637851-2789@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Ubamatamab: Phase 1/2 readout est. (NCT07637851)
DESCRIPTION:Ubamatamab\, phase 1/2\, Ovarian Cancer.\nStudy: Safety and Eff
 icacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer\nEstima
 ted primary completion: September 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ubamatamab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07637851
URL:https://assetmemo.bio/drug/ubamatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816666-11153@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280929
DTEND;VALUE=DATE:20280930
SUMMARY:Torvutatug samrotecan: Phase 3 readout est. (NCT07816666)
DESCRIPTION:Torvutatug samrotecan\, phase 3\, Ovarian Cancer.\nStudy: Torvu
 tatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of P
 latinum-sensitive Relapsed Epithelial Ovarian Cancer\nEstimated primary co
 mpletion: 29 September 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/torvutatug-samrotecan#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07816666
URL:https://assetmemo.bio/drug/torvutatug-samrotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843303-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07843303)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Trastuzumab Rez
 etecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer\nEs
 timated primary completion: 30 September 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07843303
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843303-9096@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07843303)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Ovarian Cancer.\nStudy: Trast
 uzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian 
 Cancer\nEstimated primary completion: 30 September 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07843303
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225270-2708@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 3 readout est. (NCT07225270)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 3\, Ovarian Cancer.\nStud
 y: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care
  Compared to Standard of Care for Maintenance Treatment of Participants Wi
 th Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Plat
 inum-based Doublet Chemotherapy\nEstimated primary completion: October 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/rinatabart-sesutec
 an-rina-s#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07225270
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06072781-11026@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20281015
DTEND;VALUE=DATE:20281016
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 3 readout
  est. (NCT06072781)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 3\, 
 Ovarian Cancer.\nStudy: A Study of Avutometinib (VS-6766) + Defactinib (VS
 -6063) in Recurrent Low-Grade Serous Ovarian Cancer\nEstimated primary com
 pletion: 15 October 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/avutometinib-defactinib-avmapki-fakzynja-co-pack#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06072781
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05086692-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20281020
DTEND;VALUE=DATE:20281021
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05086692)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Beta-only IL-2 ImmunoTherapY Study\nEstimated primary completion: 20 Oc
 tober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05086692
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05952453-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05952453)
DESCRIPTION:Pembrolizumab\, phase 2\, Ovarian Cancer.\nStudy: Newly Diagnos
 ed Stage III/IV Ovarian Cancer\, Neoadjuvant Carbo/Taxol/Pembro\, Maintena
 nce Olaparib/Pembro\nEstimated primary completion: 30 October 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05952453
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05952453-2028@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Olaparib: Phase 2 readout est. (NCT05952453)
DESCRIPTION:Olaparib\, phase 2\, Ovarian Cancer.\nStudy: Newly Diagnosed St
 age III/IV Ovarian Cancer\, Neoadjuvant Carbo/Taxol/Pembro\, Maintenance O
 laparib/Pembro\nEstimated primary completion: 30 October 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05952453
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07213804-2607@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Sofetabart mipitecan: Phase 3 readout est. (NCT07213804)
DESCRIPTION:Sofetabart mipitecan\, phase 3\, Ovarian Cancer.\nStudy: A Thre
 e-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum
 -Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer\
 nEstimated primary completion: November 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/sofetabart-mipitecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07213804
URL:https://assetmemo.bio/drug/sofetabart-mipitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04590326-2789@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20281108
DTEND;VALUE=DATE:20281109
SUMMARY:Ubamatamab: Phase 1/2 readout est. (NCT04590326)
DESCRIPTION:Ubamatamab\, phase 1/2\, Ovarian Cancer.\nStudy: A Study to Fin
 d Out How Safe REGN5668 is and How Well it Works In Adult Women When Given
  With Either Cemiplimab\, or Cemiplimab + Fianlimab\, or Ubamatamab\nEstim
 ated primary completion: 8 November 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ubamatamab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04590326
URL:https://assetmemo.bio/drug/ubamatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04590326-11311@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20281108
DTEND;VALUE=DATE:20281109
SUMMARY:REGN5668: Phase 1/2 readout est. (NCT04590326)
DESCRIPTION:REGN5668\, phase 1/2\, Ovarian Cancer.\nStudy: A Study to Find 
 Out How Safe REGN5668 is and How Well it Works In Adult Women When Given W
 ith Either Cemiplimab\, or Cemiplimab + Fianlimab\, or Ubamatamab\nEstimat
 ed primary completion: 8 November 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/regn5668#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04590326
URL:https://assetmemo.bio/drug/regn5668#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07218809-11153@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20281117
DTEND;VALUE=DATE:20281118
SUMMARY:Torvutatug samrotecan: Phase 3 readout est. (NCT07218809)
DESCRIPTION:Torvutatug samrotecan\, phase 3\, Ovarian Cancer.\nStudy: AZD53
 35 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy
  in FRα-low Platinum-resistant Ovarian Cancer\nEstimated primary completi
 on: 17 November 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /torvutatug-samrotecan#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07218809
URL:https://assetmemo.bio/drug/torvutatug-samrotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05579366-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05579366)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Rinatabart Sesutecan (Rina-S\, PRO1184\, GEN1184) for Advanced Solid Tumo
 rs (GCT1184-01/ PRO1184-001)\nEstimated primary completion: December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05579366
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05579366-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05579366)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: R
 inatabart Sesutecan (Rina-S\, PRO1184\, GEN1184) for Advanced Solid Tumors
  (GCT1184-01/ PRO1184-001)\nEstimated primary completion: December 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05579366
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05579366-2708@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 1/2 readout est. (NCT05579366)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 1/2\, Non-Small Cell Lung
  Cancer.\nStudy: Rinatabart Sesutecan (Rina-S\, PRO1184\, GEN1184) for Adv
 anced Solid Tumors (GCT1184-01/ PRO1184-001)\nEstimated primary completion
 : December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rina
 tabart-sesutecan-rina-s#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05579366
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07545460-2282@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT07545460)
DESCRIPTION:Trastuzumab brengitecan\, phase 3\, Ovarian Cancer.\nStudy: A S
 tudy Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patient
 s With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Can
 cer\, Fallopian Tube Cancer\, and Primary Peritoneal Cancer\nEstimated pri
 mary completion: December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/trastuzumab-brengitecan#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07545460
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05009082-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05009082)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: Niraparib vs Ni
 raparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemothera
 py in Advanced Ovarian Cancer\nEstimated primary completion: December 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05009082
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05009082-2052@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Niraparib: Phase 3 readout est. (NCT05009082)
DESCRIPTION:Niraparib\, phase 3\, Ovarian Cancer.\nStudy: Niraparib vs Nira
 parib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy
  in Advanced Ovarian Cancer\nEstimated primary completion: December 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/niraparib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05009082
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410676-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07410676)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab
  in Advanced Solid Tumors\nEstimated primary completion: 21 December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07410676
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01174121-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20281227
DTEND;VALUE=DATE:20281228
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT01174121)
DESCRIPTION:Pembrolizumab\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients Wit
 h Metastatic Cancer\nEstimated primary completion: 27 December 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT01174121
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059845-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07059845)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: A Study to Asse
 ss Adverse Events and Change in Disease Activity of Multiple Treatment Com
 binations With Intravenous Mirvetuximab Soravtansine in Adult Participants
  With Ovarian Cancer\nEstimated primary completion: January 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07059845
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059845-11140@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT07059
 845)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2\, Ovarian Cancer.
 \nStudy: A Study to Assess Adverse Events and Change in Disease Activity o
 f Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansi
 ne in Adult Participants With Ovarian Cancer\nEstimated primary completion
 : January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mirve
 tuximab-soravtansine#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07059845
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06843447-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290327
DTEND;VALUE=DATE:20290328
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06843447)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Ovarian Cancer.\nStudy: A Clinical 
 Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003
 ).\nEstimated primary completion: 27 March 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06843447
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06843447-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290327
DTEND;VALUE=DATE:20290328
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06843447)
DESCRIPTION:Bevacizumab\, phase 1/2\, Ovarian Cancer.\nStudy: A Clinical St
 udy of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
 \nEstimated primary completion: 27 March 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06843447
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06843447-2696@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290327
DTEND;VALUE=DATE:20290328
SUMMARY:Raludotatug Deruxtecan: Phase 1/2 readout est. (NCT06843447)
DESCRIPTION:Raludotatug Deruxtecan\, phase 1/2\, Ovarian Cancer.\nStudy: A 
 Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK
 -5909-003).\nEstimated primary completion: 27 March 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06843447
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07663513-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07663513)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Iparomlimab and
  Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadj
 uvant Therapy for Advanced Ovarian Cancer\nEstimated primary completion: A
 pril 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 663513
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07504588-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290412
DTEND;VALUE=DATE:20290413
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07504588)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Sacituzumab Gov
 itecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin\, Pegy
 lated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platin
 um-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy\nEsti
 mated primary completion: 12 April 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07504588
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06824467-1991@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290427
DTEND;VALUE=DATE:20290428
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06824467)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Ovarian Cancer.\nStudy: A S
 tudy to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-28
 70) Maintenance Treatment Versus Standard of Care in Participants With Pla
 tinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov
 84/GOG-3103)\nEstimated primary completion: 27 April 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06824467
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07791732-2696@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Raludotatug Deruxtecan: Phase 3 readout est. (NCT07791732)
DESCRIPTION:Raludotatug Deruxtecan\, phase 3\, Ovarian Cancer.\nStudy: A St
 udy of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maint
 enance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer 
 (REJOICE-Ovarian03)\nEstimated primary completion: 1 July 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07791732
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05659381-2052@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Niraparib: Phase 3 readout est. (NCT05659381)
DESCRIPTION:Niraparib\, phase 3\, Ovarian Cancer.\nStudy: Heated Intraperit
 oneal Chemotherapy Followed by Niraparib for Ovarian\, Primary Peritoneal 
 and Fallopian Tube Cancer\nEstimated primary completion: 1 August 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/niraparib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05659381
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07694427-9165@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20290906
DTEND;VALUE=DATE:20290907
SUMMARY:GSK 5733584: Phase 3 readout est. (NCT07694427)
DESCRIPTION:GSK 5733584\, phase 3\, Ovarian Cancer.\nStudy: Mo-Rez in First
 - Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficien
 t Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]\nEstimated primary comple
 tion: 6 September 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/gsk-5733584#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07694427
URL:https://assetmemo.bio/drug/gsk-5733584#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07564141-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07564141)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: Study to Assess
  the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to
  Investigator's Choice of Platinum-based Chemotherapy With or Without Beva
 cizumab as Second-line Treatment in Participants With Recurrent Platinum-s
 ensitive Ovarian Cancer\nEstimated primary completion: December 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07564141
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07564141-2708@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 3 readout est. (NCT07564141)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 3\, Ovarian Cancer.\nStud
 y: Study to Assess the Efficacy and Safety of Rina-S With or Without Bevac
 izumab Compared to Investigator's Choice of Platinum-based Chemotherapy Wi
 th or Without Bevacizumab as Second-line Treatment in Participants With Re
 current Platinum-sensitive Ovarian Cancer\nEstimated primary completion: D
 ecember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rinatab
 art-sesutecan-rina-s#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07564141
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07821606-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07821606)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: Phase III Study
  of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Canc
 er\nEstimated primary completion: 30 December 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07821606
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07370818-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07370818)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: To Evaluate the
  Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Mainten
 ance Therapy in Relapsed Ovarian Cancer\nEstimated primary completion: 31 
 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevaci
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07370818
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890338-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06890338)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: A Study to Asse
 ss Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirv
 etuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor
  Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian\, Fallopi
 an Tube or Primary Peritoneal Cancer.\nEstimated primary completion: Febru
 ary 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT068
 90338
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890338-11140@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT06890
 338)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2\, Ovarian Cancer.
 \nStudy: A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infus
 ed Carboplatin With Mirvetuximab Soravtansine in Participants With Newly D
 iagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epit
 helial Ovarian\, Fallopian Tube or Primary Peritoneal Cancer.\nEstimated p
 rimary completion: February 2030. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/mirvetuximab-soravtansine#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06890338
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07779538-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07779538)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: Clinical Trials
  Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Mai
 ntenance Therapy for Epithelial Ovarian Cancer\nEstimated primary completi
 on: 28 February 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07779538
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07859215-2708@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 3 readout est. (NCT07859215)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 3\, Ovarian Cancer.\nStud
 y: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care
  Compared to Standard of Care Maintenance Treatment After First-line (1L) 
 Platinum-based Chemotherapy in Participants With Ovarian Cancer\nEstimated
  primary completion: March 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07859215
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06954584-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20300501
DTEND;VALUE=DATE:20300502
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT06954584)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: Fluzoparib+Beva
 cizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maint
 enance in HRD+/- Advanced Ovarian Cancer\nEstimated primary completion: 1 
 May 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 54584
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684612-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20300521
DTEND;VALUE=DATE:20300522
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07684612)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: A Study to Inve
 stigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doubl
 et With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer
  (BEHOLD-Ovarian02)\nEstimated primary completion: 21 May 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07684612
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684612-9165@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20300521
DTEND;VALUE=DATE:20300522
SUMMARY:GSK 5733584: Phase 3 readout est. (NCT07684612)
DESCRIPTION:GSK 5733584\, phase 3\, Ovarian Cancer.\nStudy: A Study to Inve
 stigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doubl
 et With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer
  (BEHOLD-Ovarian02)\nEstimated primary completion: 21 May 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/gsk-5733584#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07684612
URL:https://assetmemo.bio/drug/gsk-5733584#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05200559-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05200559)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Ovarian Cancer.\nStudy: T-regulator
 y Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Me
 tastatic Solid Tumors\nEstimated primary completion: 31 May 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05200559
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06990516-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06990516)
DESCRIPTION:Bevacizumab\, phase 1/2\, Ovarian Cancer.\nStudy: SHR - A1811 I
 njection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer\n
 Estimated primary completion: 1 June 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06990516
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06990516-9096@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Trastuzumab rezetecan: Phase 1/2 readout est. (NCT06990516)
DESCRIPTION:Trastuzumab rezetecan\, phase 1/2\, Ovarian Cancer.\nStudy: SHR
  - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovaria
 n Cancer\nEstimated primary completion: 1 June 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06990516
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06990503-9096@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT06990503)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Ovarian Cancer.\nStudy: SHR -
  A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ova
 rian Cancer\nEstimated primary completion: 1 June 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06990503
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07851025-11153@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20300628
DTEND;VALUE=DATE:20300629
SUMMARY:Torvutatug samrotecan: Phase 3 readout est. (NCT07851025)
DESCRIPTION:Torvutatug samrotecan\, phase 3\, Ovarian Cancer.\nStudy: Torvu
 tatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homolog
 ous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovaria
 n Cancer\nEstimated primary completion: 28 June 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/torvutatug-samrotecan#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07851025
URL:https://assetmemo.bio/drug/torvutatug-samrotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286266-9165@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20300722
DTEND;VALUE=DATE:20300723
SUMMARY:GSK 5733584: Phase 3 readout est. (NCT07286266)
DESCRIPTION:GSK 5733584\, phase 3\, Ovarian Cancer.\nStudy: A Study to Inve
 stigate Mocertatug Rezetecan Compared With Standard of Care in Participant
 s With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)\nEstimated pri
 mary completion: 22 July 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/gsk-5733584#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07286266
URL:https://assetmemo.bio/drug/gsk-5733584#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647653-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07647653)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Fluzoparib + Be
 vacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positiv
 e Advanced Ovarian Cancer\nEstimated primary completion: 28 February 2031.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07647653
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647653-2028@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Olaparib: Phase 2 readout est. (NCT07647653)
DESCRIPTION:Olaparib\, phase 2\, Ovarian Cancer.\nStudy: Fluzoparib + Bevac
 izumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive A
 dvanced Ovarian Cancer\nEstimated primary completion: 28 February 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07647653
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743164-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07743164)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: A Clinical Tria
 l of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Partici
 pants With Ovarian Cancer Who Have Progressed During Treatment With PARP-i
 nhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG
 -3142 / REJOICE-Ovarian05)\nEstimated primary completion: 31 August 2031. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07743164
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743164-2696@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Raludotatug Deruxtecan: Phase 3 readout est. (NCT07743164)
DESCRIPTION:Raludotatug Deruxtecan\, phase 3\, Ovarian Cancer.\nStudy: A Cl
 inical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab
  in Participants With Ovarian Cancer Who Have Progressed During Treatment 
 With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGO
 T-ov107/GOG-3142 / REJOICE-Ovarian05)\nEstimated primary completion: 31 Au
 gust 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/raludotatu
 g-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07743164
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720180-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20311201
DTEND;VALUE=DATE:20311202
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07720180)
DESCRIPTION:Pembrolizumab\, phase 2\, Ovarian Cancer.\nStudy: Study of Auto
 logous\, Metabolically Optimized\, CD137+ Tumor-Infiltrating Lymphocytes F
 ollowed by Consolidative Oral Cyclophosphamide\, Bevacizumab\, and Pembrol
 izumab\nEstimated primary completion: 1 December 2031. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07720180
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720180-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20311201
DTEND;VALUE=DATE:20311202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07720180)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Study of Autolo
 gous\, Metabolically Optimized\, CD137+ Tumor-Infiltrating Lymphocytes Fol
 lowed by Consolidative Oral Cyclophosphamide\, Bevacizumab\, and Pembroliz
 umab\nEstimated primary completion: 1 December 2031. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07720180
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07776691-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20320319
DTEND;VALUE=DATE:20320320
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07776691)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: A Study of Ralu
 dotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance T
 reatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006\, (ENGOT
 -ov102/GOG-3141/ REJOICE-Ovarian 04)\nEstimated primary completion: 19 Mar
 ch 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0777
 6691
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07776691-2696@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20320319
DTEND;VALUE=DATE:20320320
SUMMARY:Raludotatug Deruxtecan: Phase 3 readout est. (NCT07776691)
DESCRIPTION:Raludotatug Deruxtecan\, phase 3\, Ovarian Cancer.\nStudy: A St
 udy of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Ma
 intenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-0
 06\, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)\nEstimated primary complet
 ion: 19 March 2032. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/r
 aludotatug-deruxtecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07776691
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797283-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20320501
DTEND;VALUE=DATE:20320502
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07797283)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: Phase 3 Study o
 f INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maint
 enance Therapy in Ovarian Cancer Overexpressing Cyclin E1\nEstimated prima
 ry completion: 1 May 2032. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07797283
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797283-10796@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20320501
DTEND;VALUE=DATE:20320502
SUMMARY:INCB123667: Phase 3 readout est. (NCT07797283)
DESCRIPTION:INCB123667\, phase 3\, Ovarian Cancer.\nStudy: Phase 3 Study of
  INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Mainte
 nance Therapy in Ovarian Cancer Overexpressing Cyclin E1\nEstimated primar
 y completion: 1 May 2032. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/incb123667#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07797283
URL:https://assetmemo.bio/drug/incb123667#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05460000-2052@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20321001
DTEND;VALUE=DATE:20321002
SUMMARY:Niraparib: Phase 2 readout est. (NCT05460000)
DESCRIPTION:Niraparib\, phase 2\, Ovarian Cancer.\nStudy: A Phase II Random
 ized\, Open Label Non-inferiority Study of NiraParib Maintenance After 3 v
 s. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced
  HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy\nEst
 imated primary completion: 1 October 2032. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/niraparib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05460000
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06915025-2028@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20321031
DTEND;VALUE=DATE:20321101
SUMMARY:Olaparib: Phase 3 readout est. (NCT06915025)
DESCRIPTION:Olaparib\, phase 3\, Ovarian Cancer.\nStudy: Phase 3 Trial Eval
 uating the Safety & Efficacy of IMNN-001 Administered in Combination w/ St
 andard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advance
 d EOC\, Fallopian Tube or Primary Peritoneal Cancer\nEstimated primary com
 pletion: 31 October 2032. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/olaparib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06915025
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06915025-2052@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20321031
DTEND;VALUE=DATE:20321101
SUMMARY:Niraparib: Phase 3 readout est. (NCT06915025)
DESCRIPTION:Niraparib\, phase 3\, Ovarian Cancer.\nStudy: Phase 3 Trial Eva
 luating the Safety & Efficacy of IMNN-001 Administered in Combination w/ S
 tandard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanc
 ed EOC\, Fallopian Tube or Primary Peritoneal Cancer\nEstimated primary co
 mpletion: 31 October 2032. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/niraparib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06915025
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318558-1991@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20330225
DTEND;VALUE=DATE:20330226
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT07318558)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Ovarian Cancer.\nStudy: A C
 linical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian 
 Cancer (MK-2870-021)\nEstimated primary completion: 25 February 2033. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07318
 558
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472140-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT07472140)
DESCRIPTION:Bevacizumab\, phase 2/3\, Ovarian Cancer.\nStudy: PARP (Poly (A
 DP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in
  Homologous Recombination Deficient Primary Ovarian Cancer\, Fallopian-Tub
 e Cancer\, or Primary Peritoneal Cancer\nEstimated primary completion: 30 
 June 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 472140
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03755739-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20331101
DTEND;VALUE=DATE:20331102
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT03755739)
DESCRIPTION:Pembrolizumab\, phase 2/3\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus C
 hemodrug for Immunotherapy of Advanced Solid Tumors\nEstimated primary com
 pletion: 1 November 2033. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT03755739
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06580314-2008@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20341231
DTEND;VALUE=DATE:20350101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT06580314)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: Testing Olapari
 b for One or Two Years\, With or Without Bevacizumab\, to Treat Ovarian Ca
 ncer\nEstimated primary completion: 31 December 2034. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06580314
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06580314-2028@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20341231
DTEND;VALUE=DATE:20350101
SUMMARY:Olaparib: Phase 3 readout est. (NCT06580314)
DESCRIPTION:Olaparib\, phase 3\, Ovarian Cancer.\nStudy: Testing Olaparib f
 or One or Two Years\, With or Without Bevacizumab\, to Treat Ovarian Cance
 r\nEstimated primary completion: 31 December 2034. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06580314
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07718854-1973@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20360930
DTEND;VALUE=DATE:20361001
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07718854)
DESCRIPTION:Pembrolizumab\, phase 2\, Ovarian Cancer.\nStudy: Sacituzumab T
 irumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovaria
 n Clear Cell Cancer\nEstimated primary completion: September 2036. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07718854
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07718854-1991@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20360930
DTEND;VALUE=DATE:20361001
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07718854)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Ovarian Cancer.\nStudy: Sac
 ituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurr
 ent Ovarian Clear Cell Cancer\nEstimated primary completion: September 203
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumo
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07718854
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
